RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the appointment of Dr. Minji Kim as its new Chief Business Officer. The move comes as part of a strategic reorganization that separates the roles of Chief Financial Officer and Chief Business Officer in response to the company’s expanding operations. Adam Levy will continue in his role as Chief Financial Officer.
Dr. Kim brings with her over two decades of experience in business development, strategic leadership, and scientific research. She has a proven track record of generating value for multiple companies by identifying and executing strategic opportunities. Her career spans leadership roles at several biotech companies both in the U.S. and overseas, across a broad range of therapeutic and technical areas.
Jon Congleton, Chief Executive Officer of Mineralys, expressed his enthusiasm about the appointment. “We are excited to have Minji join our team,” he said, adding that the company is pleased to start 2024 with its full executive team in place. This comes as they focus on the late-stage clinical development of lorundrostat, a treatment for aldosterone-dependent conditions such as hypertension and chronic kidney disease.
Dr. Kim also shared her excitement about joining Mineralys. She noted the significant potential of lorundrostat, particularly given the current trajectory of the ongoing pivotal clinical development program. She highlighted the drug’s potential to address unmet needs in patients suffering from diseases driven by abnormally elevated aldosterone.
Before joining Mineralys, Dr. Kim held the role of Chief Business Officer at Affamed Therapeutics and General Manager at Affamed Digital. During her tenure, she succeeded in bringing multiple products into their pipeline. Prior roles include Head of Business Development and Alliance Management at Jounce Therapeutics, Vice President of Corporate and Business Development at Curis, Inc., and working within the Global Oncology Business Development and Licensing group at Hoffmann-La Roche. She currently serves as an independent board member of SK Biopharmaceuticals.
Dr. Kim’s appointment comes at a crucial time for Mineralys, with several clinical milestones for lorundrostat expected over the next 12-18 months. Investors will undoubtedly watch closely to see how her strategic leadership impacts the company’s progress.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.